<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04534218</url>
  </required_header>
  <id_info>
    <org_study_id>2020/490</org_study_id>
    <nct_id>NCT04534218</nct_id>
  </id_info>
  <brief_title>Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer</brief_title>
  <acronym>REPROGRAM-01</acronym>
  <official_title>Regorafenib in Combination With Metronomic Cyclophosphamide, Capecitabine, and Low-dose Aspirin in Metastatic Colorectal Cancer Carcinoma An Open-label Phase II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose a phase II clinical trial with the objective to investigate the&#xD;
      potential clinical interest to associate regorafenib with a metronomic chemotherapy combining&#xD;
      capecitabine, cyclophosphamide and low-dose aspirin, for the treatment of patients with&#xD;
      metastatic colorectal cancer. The main objective of the study will be to achieve 15% of&#xD;
      objective response rate in patients treated with multimodal metronomic chemotherapy and&#xD;
      regorafenib.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 16, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>From date of inclusion until end of treatment for the patient, assessed to 4 months</time_frame>
    <description>The objective response rate (ORR) will be defined by RECIST v1.1 criteria as the best disease response observed during the treatment period (assessed to 4 months). ORR rate is defined as the proportion of patients whose tumor regresses or does not progress under treatment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Colo-rectal Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REGORAFENIB:&#xD;
For the first cycle: regorafenib will be administered according to the &quot;REDOS&quot; schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).&#xD;
For the following cycles: regorafenib will be administered at a 80, 120 or 160 mg daily dose according to toxicity observed with the last dose used in the first cycle.&#xD;
METRONOMIC CHEMOTHERAPIES:&#xD;
Capecitabine: 625mg/m²/orally twice daily continuously for 6 months&#xD;
Cyclophosphamide: 50 mg per os, daily, for 6 months&#xD;
ASPIRIN:&#xD;
75 mg orally and daily until progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>For the first cycle: regorafenib will be administered according to the &quot;REDOS&quot; schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).&#xD;
For the following cycles: regorafenib will be administered at a 80, 120 or 160 mg daily dose according to toxicity observed with the last dose used in the first cycle.</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Stivarga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>50 mg per os, daily, for 6 months</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>625mg/m²/orally twice daily continuously for 6 months</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>75 mg orally and daily until progression</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Kardegic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically proven metastatic colorectal cancer in progression after&#xD;
             previous standard treatments (5FU, CPT11, oxaliplatin, anti-VEGF and anti-EGFR therapy&#xD;
             if KRAS and NRAS WT), or not considered as candidate for these treatments&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Female or male with age &gt;18 years old&#xD;
&#xD;
          -  Performance status = 0 or 1 (Annex 1)&#xD;
&#xD;
          -  Measurable disease defined according to RECIST v1.1 (scanner or MRI) (Annex 2)&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal functions.&#xD;
&#xD;
               1. Haemoglobin ≥ 9 g/dL; absolute neutrophil count (ANC) ≥ 1.5 x 109/L; platelets ≥&#xD;
                  100 x 109/L&#xD;
&#xD;
               2. Total serum bilirubin ≤ 1.5 times upper normal value (ULN), serum alkaline&#xD;
                  phosphatase &lt; 5 times ULN, aminotransferases (AST/ALT) ≤ 3 × ULN in absence of&#xD;
                  hepatic metastasis or ≤ 5 if presence of hepatic lesions&#xD;
&#xD;
               3. Cockcroft glomerular filtration rate &gt; 50 ml/min&#xD;
&#xD;
               4. Proteinuria &lt;2+ (dipstick urinalysis) or ≤1g/24hour&#xD;
&#xD;
          -  Imaging target greater than one cm must be visible on CT,&#xD;
&#xD;
          -  No contraindication to Iodine contrast media injection during CT&#xD;
&#xD;
          -  For female patients of childbearing potential, negative pregnancy test within 14 days&#xD;
             before starting the study drug. Men and women are required to use adequate birth&#xD;
             control during the study (when applicable),&#xD;
&#xD;
          -  Signed and dated informed consent,&#xD;
&#xD;
          -  Ability to comply with the study protocol, in the Investigator's judgment.&#xD;
&#xD;
          -  Registration in a national health care system (CMU included).&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Diagnosis of additional malignancy within 2 years prior to the inclusion (exception of&#xD;
             curatively treated basal cell carcinoma of the skin and/or curatively resected in situ&#xD;
             cervical cancer),&#xD;
&#xD;
          -  Current participation in a study of an investigational agent or in the period of&#xD;
             exclusion&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule; those conditions&#xD;
             should be discussed with the patient before inclusion in the trial ;&#xD;
&#xD;
          -  Patient under judicial protection (curatorship, tutorship) and/or deprived of freedom,&#xD;
&#xD;
          -  Planned surgical procedure within the first month of treatment or any procedure that&#xD;
             might change the timing of regorafenib administration during the first month of&#xD;
             treatment,&#xD;
&#xD;
          -  Previous exposure to regorafenib,&#xD;
&#xD;
          -  Previous exposure to other anti-angiogenic treatment than bevacizumab and aflibercept,&#xD;
&#xD;
          -  Complete deficit in dihydropyrimidine deshydrogenase (DPD),&#xD;
&#xD;
          -  Major surgical procedure, open biopsy or significant traumatic injury within 28 days&#xD;
             before start of study medication,&#xD;
&#xD;
          -  Pregnant or breast-feeding subjects,&#xD;
&#xD;
          -  Congestive Heart Failure ≥ New York Heart Association (NYHA) class 2, unstable angina&#xD;
             (anginal symptomatology at rest),&#xD;
&#xD;
          -  Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3&#xD;
             months),&#xD;
&#xD;
          -  Myocardial infarction less than 6 months before start of study drug,&#xD;
&#xD;
          -  Cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin are&#xD;
             permitted),&#xD;
&#xD;
          -  Uncontrolled hypertension (Systolic blood pressure &gt;150 mmHg and/or diastolic pressure&#xD;
             &gt;100 mmHg despite optimal medical management), or history of hypertensive crisis, or&#xD;
             hypertensive encephalopathy&#xD;
&#xD;
          -  Pleural effusion or ascites that causes respiratory compromise (≥ CTCAE grade 2&#xD;
             dyspnea),&#xD;
&#xD;
          -  Ongoing infection &gt;grade 2 CTCAE V5,&#xD;
&#xD;
          -  Known History of human immunodeficiency virus (HIV) infection,&#xD;
&#xD;
          -  Active hepatitis B or C or chronic hepatitis B or C requiring treatment with antiviral&#xD;
             therapy,&#xD;
&#xD;
          -  Subjects with seizure disorder requiring medication,&#xD;
&#xD;
          -  History of organ allograft,&#xD;
&#xD;
          -  Subjects with evidence or history of any bleeding diathesis, irrespective of severity,&#xD;
&#xD;
          -  Any haemorrhage or bleeding event ≥ CTCAE Grade 3 within 4 weeks prior to the start of&#xD;
             study medication,&#xD;
&#xD;
          -  Serious, Non-healing wound, active ulcer or untreated bone fracture,&#xD;
&#xD;
          -  History of abdominal fistula, GI perforation, intra-abdominal abscess or active GI&#xD;
             bleeding within 6 months prior to inclusion,&#xD;
&#xD;
          -  Dehydration CTCAE v5 grade ≥1,&#xD;
&#xD;
          -  Known hypersensitivity to any of the study drugs, study drug classes or excipient in&#xD;
             the formulation,&#xD;
&#xD;
          -  Interstitial lung disease with ongoing signs or symptoms,&#xD;
&#xD;
          -  Persistent proteinuria of CTCAE Grade 3 (&gt;3.5 g/24 hours),&#xD;
&#xD;
          -  Subject unable to swallow oral medications,&#xD;
&#xD;
          -  Any malabsorption condition, unresolved toxicity higher than CTCAE (V5) Grade 1&#xD;
             attributed to any prior therapy/procedure excluding alopecia, hypothyroidism and&#xD;
             oxaliplatin induced neuropathy ≤ Grade 2,&#xD;
&#xD;
          -  Systemic anticancer therapy including cytotoxic therapy, signal transduction&#xD;
             inhibitors, immunotherapy, and hormonal therapy during this trial or within 3 weeks,&#xD;
&#xD;
          -  Treatment with any other investigational medicinal product within 28 days prior to&#xD;
             study entry, EXCEPT for ASPIRIN,&#xD;
&#xD;
          -  Co-administration of drugs potentially interacting with regorafenib i.e. CYP3A4,&#xD;
             CYP2C9 or UGT1A9 inducers/inhibitors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marine JARY</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Besançon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord Franche-Comté</name>
      <address>
        <city>Montbéliard</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 16, 2020</study_first_submitted>
  <study_first_submitted_qc>August 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>regorafenib</keyword>
  <keyword>metronomic chemotherapy</keyword>
  <keyword>colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

